Boehringer Ingelheim sharpens retinal strategy, scooping up dry AMD drug from a Swiss team behind Novartis' Beovu
Boehringer Ingelheim has inked a second deal for retinal diseases in a year — and this time it’s specific about which ailment to target.
In a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
